PMID: 20179744
doi: 10.1016/j.physbeh.2016.03.016 [DOI] [PubMed] [Google Scholar] 227
The landmark PANTHEON trial, a 1-year multicenter RCT in 1,006 Chinese COPD patients, found that high-dose NAC (600 mg twice daily) reduced the rate of acute exacerbations by 22% compared to placebo (1.16 vs 1.49 exacerbations per year, p=0.0011) (Zheng et al., Lancet Respir Med, 2014) [44]
Myocarditis has gained significant attention on social media due to its association with both COVID-19 and COVID-19 vaccinations
Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: a randomized, placebo-controlled, crossover study
Other discontinuation criteria may include severe adverse events (AEs) that cannot be managed by dose reductions or pausing the medication, a lack of impact on hyperphagia after 12 months of treatment, or significant issues with nonadherence